Search

Search Constraints

You searched for: Author/Creator Soulié, Cathia

Search Results

2. Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19. (January 2021)

3. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study—authors' response. (20th September 2019)

4. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study—authors' response. (20th September 2019)

5. Erratum to: Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients. (17th September 2021)

6. Evolution of viral quasispecies during SARS-CoV-2 infection. (November 2020)

7. Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey. (7th July 2021)

8. Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. (24th August 2015)

9. Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. (24th August 2015)

10. Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). Issue 6 (June 2022)